Granza Bio

Granza Bio is a biotechnology firm pioneering a cutting-edge delivery platform designed to precisely target therapeutic payloads to specific tissues within the body. Their innovative delivery vehicles leverage non-immunogenic proteins, engineered with targeting receptors, to achieve targeted tropism to organs of interest. These proprietary vehicles exhibit superior stability compared to traditional lipid nanoparticles (LNPs) and are capable of encapsulating diverse therapeutic cargo, including proteins, DNA, and RNA.

Granza Bio's primary focus involves harnessing the immune system's potent arsenal of "attack particles." By leveraging their advanced delivery platform, they aim to direct these "attack particles" against a spectrum of diseases, including cancer, autoimmune disorders, and infectious diseases. For further information, please contact info@granzabio.com.